Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: SYMBICORT

« Back to Dashboard

Symbicort is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug.

The generic ingredient in SYMBICORT is budesonide; formoterol fumarate dihydrate. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the budesonide; formoterol fumarate dihydrate profile page.

Summary for Tradename: SYMBICORT

Patents:13
Applicants:1
NDAs:1
Suppliers: see list1
2013 Sales:$1,563,242,000

Clinical Trials for: SYMBICORT

Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia
Status: Completed Condition: Asthma

A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
Status: Completed Condition: Asthma

Long-Term Safety of Symbicort in Asthmatic Children - SAPLING
Status: Completed Condition: Asthma

Comparing Bronchodilation of Symbicort With and With Out Valved Holding Chamber (Aerochamber Plus)
Status: Recruiting Condition: Asthma

Symbicort Rapihaler Therapeutic Equivalence Study
Status: Completed Condition: Bronchial Asthma

Atlantis Symbicort
Status: Completed Condition: Asthma

Gemini Symbicort pMDI
Status: Completed Condition: Mild or Moderate Asthma

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)
Status: Recruiting Condition: Asthma

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects
Status: Completed Condition: COPD

Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients
Status: Completed Condition: Asthma; Asthma Chronic; Asthma Bronchial; Asthmatic

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
SYMBICORT
budesonide; formoterol fumarate dihydrate
AEROSOL, METERED;INHALATION021929Jul 21, 2006RXYes8,616,196<disabled>Y<disabled>
Astrazeneca
SYMBICORT
budesonide; formoterol fumarate dihydrate
AEROSOL, METERED;INHALATION021929Jul 21, 2006RXYes8,461,211<disabled><disabled>
Astrazeneca
SYMBICORT
budesonide; formoterol fumarate dihydrate
AEROSOL, METERED;INHALATION021929Jul 21, 2006RXYes5,674,860<disabled>Y<disabled>
Astrazeneca
SYMBICORT
budesonide; formoterol fumarate dihydrate
AEROSOL, METERED;INHALATION021929Jul 21, 2006RXYes8,387,615<disabled>Y<disabled>
Astrazeneca
SYMBICORT
budesonide; formoterol fumarate dihydrate
AEROSOL, METERED;INHALATION021929Jul 21, 2006RXYes7,587,988<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc